*Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston

†Department of Pathology, Cleveland Clinic, Cleveland, MA

‡INSERM 1052, CNRS 5286, Cancer Research Center of Lyon

∥Department of Biopathology, Centre Leon Bernard, Lyon

§Department of Pathology, Universitary Hospital of Reims, Reims, France

Conflicts of Interest and Source of Funding: J.H. is supported by the Bertarelli Rare Cancers Fund at Harvard Medical School; F.B. is supported by ITMO Cancer of Aviesan within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm. For the remaining authors none were declared.

Correspondence: Arnaud de la Fouchardière, MD, PhD, Département de Biopathologie, Centre Léon Bérard, 28, rue Laennec, Lyon 69008, France (e-mail: [email protected]).